Trv Gp Vi LLC Purchases Shares of 194,174 Tango Therapeutics, Inc. $TNGX

Trv Gp Vi LLC acquired a new position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) in the 2nd quarter, Holdings Channel reports. The fund acquired 194,174 shares of the company’s stock, valued at approximately $6,069,879,000. Tango Therapeutics makes up about 2.6% of Trv Gp Vi LLC’s portfolio, making the stock its 4th biggest holding.

Several other large investors have also modified their holdings of the stock. Global Retirement Partners LLC purchased a new position in shares of Tango Therapeutics in the 4th quarter valued at $35,000. Dynamic Technology Lab Private Ltd lifted its position in Tango Therapeutics by 139.7% in the first quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock valued at $35,000 after acquiring an additional 15,037 shares during the last quarter. Legal & General Group Plc lifted its position in Tango Therapeutics by 30.7% in the second quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock valued at $36,000 after acquiring an additional 1,640 shares during the last quarter. ANTIPODES PARTNERS Ltd acquired a new position in Tango Therapeutics in the fourth quarter valued at $40,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Tango Therapeutics by 148,800.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company’s stock worth $40,000 after purchasing an additional 4,464 shares during the last quarter. Institutional investors and hedge funds own 78.99% of the company’s stock.

Tango Therapeutics Stock Performance

Shares of TNGX opened at $25.44 on Wednesday. Tango Therapeutics, Inc. has a fifty-two week low of $6.25 and a fifty-two week high of $34.39. The company has a market capitalization of $4.29 billion, a price-to-earnings ratio of -29.93 and a beta of 1.16. The firm has a 50-day simple moving average of $28.69 and a 200-day simple moving average of $22.51.

Tango Therapeutics (NASDAQ:TNGX) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.05). Equities research analysts forecast that Tango Therapeutics, Inc. will post -1.36 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Wall Street Zen cut Tango Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. Leerink Partners upped their target price on Tango Therapeutics from $55.00 to $69.00 and gave the company an “outperform” rating in a research report on Monday, June 8th. Wolfe Research set a $35.00 price target on Tango Therapeutics and gave the stock an “outperform” rating in a research note on Monday, June 8th. B. Riley Financial reaffirmed a “buy” rating on shares of Tango Therapeutics in a research report on Monday, June 8th. Finally, Guggenheim boosted their price objective on Tango Therapeutics from $32.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Thirteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Tango Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $43.46.

Insider Activity

In other news, insider Adam Crystal sold 27,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $29.59, for a total value of $798,930.00. Following the transaction, the insider owned 115,743 shares of the company’s stock, valued at approximately $3,424,835.37. The trade was a 18.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 6.50% of the company’s stock.

Tango Therapeutics Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.